Prof. Linghua Li | Cancer Science | Best Researcher Award

Prof. Linghua Li | Cancer Science | Best Researcher Award

Guangzhou Eighth People’s Hospital | China

Author Profile

ORCID ID

🌟Linghua Li, Ph.D., M.S., B.S. 🌍

Head Director, Infectious Disease Center
Guangzhou Eighth People’s Hospital, Guangzhou Medical University

👩‍⚕️Biography

Dr. Linghua Li is a distinguished physician and researcher specializing in HIV/AIDS, infectious diseases, and oncology. With over 25 years of clinical experience, she has made significant contributions to understanding and managing infectious diseases, particularly fungal infections and HIV-related complications.

Dr. Li began her academic journey at the Medical School of Peking University, earning a B.S. in Clinical Medicine in 1997. She then pursued advanced studies at Sun Yat-sen University, completing an M.S. in Internal Medicine in 2008 and a Ph.D. in Infectious Diseases in 2011. She further enriched her expertise through visiting scholar positions at UNC-Chapel Hill (2012) and Duke University (2014), focusing on infectious diseases.

As the Head Director of the Infectious Disease Center at Guangzhou Eighth People’s Hospital, Dr. Li oversees clinical trials, patient care, and research initiatives for people living with HIV and at-risk populations. She has been principal investigator (PI) or co-investigator (Co-I) on more than 20 domestic and international research programs. Notable projects include:

  • National Natural Science Foundation of China (Grant No. 81301480): Investigating the mechanism and function of Phospholipase B in the growth and pathogenicity of P. marneffei.
  • Guangdong Natural Science Foundation (Grant No. 10151006002000000): Exploring the role of Phospholipase B in P. marneffei invasion of macrophages in AIDS patients.
  • NIH Fogarty Program: Examining host factors in severe opportunistic complications of AIDS, with a focus on developing targeted prophylactic strategies.

In recent years, Dr. Li has been a Co-PI on groundbreaking HIV PrEP Phase IV clinical trials in Guangzhou, including:

  • ChiCTR2100048981 and NCT04754139: These studies focus on scaling PrEP access for key populations in China. The trial successfully enrolled 1,007 participants by 2023, with 950 already on PrEP, marking it as the largest trial of its kind in China.

Dr. Li’s work emphasizes translational medicine, data-driven public health strategies, and the implementation of novel interventions like PrEP to curb HIV transmission. Her expertise in site coordination, implementation, data collection, and analysis has been pivotal to these efforts.

🧬Key Areas of Expertise

🔬 HIV Prevention and Treatment
🌿 Opportunistic Infections
📊 Clinical Trials and Data Analysis
🧑‍⚕️ Internal and Infectious Diseases

📚Academic Background

  • B.S., Clinical Medicine, Medical School of Peking University (1997)
  • M.S., Internal Medicine, Sun Yat-sen University (2008)
  • Ph.D., Infectious Diseases, Sun Yat-sen University (2011)
  • Visiting Scholar, UNC-Chapel Hill (2012)
  • Visiting Scholar, Duke University (2014)

🔬Research Impact

🌟 Over 20 funded research projects
📄 Numerous publications in infectious disease and public health journals
📚 Active contributor to advancing HIV prevention strategies in China

Dr. Linghua Li remains a leader in the fight against infectious diseases, with a career dedicated to improving global health outcomes. 🌏✨

✨ Conclusion

Dr. Linghua Li’s career exemplifies dedication to advancing the prevention, treatment, and understanding of infectious diseases, particularly HIV/AIDS and associated complications. Through her leadership, innovative research, and clinical expertise, she has significantly impacted global health, especially in developing effective interventions like PrEP for key populations in China. Her contributions to translational medicine and public health continue to pave the way for breakthroughs in managing infectious diseases and improving the lives of those affected worldwide. 🌟🌍

📊🔬NOTABLE PUBLICATION:
  • Utilizing Protein–Peptide Hybrid Microarray for Time-Resolved Diagnosis and Prognosis of COVID-19
    • Authors: Peiyan Zheng, Baolin Liao, Jiao Yang, Hu Cheng, Zhangkai Cheng, Huimin Huang, Wenting Luo, Yiyue Sun, Qiang Zhu, Yi Deng, et al.
    • Journal: Microorganisms
    • Year: 2023

Dr. Wenjin Wang | Targeted Cancer Therapy | Young Scientist Award

Dr. Wenjin Wang | Targeted Cancer Therapy | Young Scientist Award

The Chinese University of Hong Kong | China

Author Profile

Scopus

Dr. Wenjin Wang 🌟🔬

Postdoctoral Researcher | Tumor Photodynamic Therapy Expert | Biomolecular Phase Separation Investigator

Research Interests

  1. Tumor Photodynamic Therapy (PDT) 💡🎯
    • Design and synthesis of novel photosensitizers for PDT.
    • Development of tumor-targeted PDT using tumor-responsive AIE (Aggregation-Induced Emission) photosensitizers.
  2. Regulation of Biomolecular Phase Separation 🧬⚛️
    • Investigation into the phase separation behaviors of biomolecules like proteins and nucleic acids.
    • Modulation of these processes with chemical molecules to enhance understanding of intracellular organization and function.

Professional Experience

  • Postdoctoral Researcher 🏢
    The Chinese University of Hong Kong, Shenzhen (07/2022–Present)

    • Research on bioapplications of AIE materials under Prof. Ben Zhong Tang.
  • Biochemical Engineer 🧪
    Shenzhen BGI Research Institute (10/2017–09/2018)

    • Designed and optimized unnatural nucleotides for sequencing applications.
  • Laboratory Assistant 🔬
    Peking University Shenzhen Graduate School (11/2016–10/2017)

    • Focused on unnatural amino acids and asymmetric carbene O-H bond insertion catalysis by myoglobin proteins.
  • Research Associate 💊
    Tianjin Institute of Pharmaceutical Research (08/2014–11/2016)

    • Developed new hypoglycemic drugs through innovative designs and research.

Education

  • Ph.D. in Chemical Biology 🧫
    Sun Yat-Sen University (09/2018–06/2022)

    • Thesis: Antitumor mechanisms of metal complexes and their regulation on biomolecular phase separation behavior.
  • M.S. in Pharmacy 💊
    Tianjin Medical University (09/2012–06/2015)

    • Research: Development of SGLT2 inhibitors and hypoglycemic activity evaluation.
  • B.S. in Pharmacy 🏥
    Tianjin Medical University (09/2008–06/2012)

Grants and Funding 💰📚

  1. National Natural Science Foundation of China
    • Ruthenium Complexes and Lipid Phase Separation in Antitumor Research (2024–2026, RMB 300K, Principal Investigator).
  2. China Postdoctoral Science Foundation
    • GGT-Activated AIE Photosensitizers for Tumor Photodynamic Therapy (2022–2025, RMB 80K, Principal Investigator).
  3. Shenzhen Medical Research Fund
    • Manipulable Aggregation of AIE Photosensitizers for Enhanced Tumor PDT (2025–2027, RMB 800K, Principal Investigator).
  4. National Natural Science Foundation of China
    • Phase Separation Mechanism of Antitumor Phosphor Metal Complexes (2022–2025, RMB 630K, Major Participant).
  5. Yunnan Province Science and Technology Plan
    • Aggregate Induced Luminescence in Biomass Resources (2024–2026, RMB 2000K, Major Participant).

Awards and Honors 🏆✨

  • Excellent Postdoctoral Doctor (Shenzhen, 12/2023).
  • National Scholarship for Doctoral Students (12/2021).
  • “Fran” Excellent Thesis Scholarship (Second Class, Sun Yat-sen University, 11/2021).
  • Excellent Wall Poster Award (32nd Academic Annual Meeting, Chinese Chemical Society, 04/2021).

Key Contributions 📈

Dr. Wang’s groundbreaking research combines innovative photodynamic therapies and the manipulation of biomolecular phase separation, driving advancements in cancer treatment and molecular biology.

📊🔬NOTABLE PUBLICATION:
  • Title: Multi-Stimuli-Responsive and Cell Membrane Camouflaged Aggregation-Induced Emission Nanogels for Precise Chemo-photothermal Synergistic Therapy of Tumors
    • Authors: Zhang, L.; Wang, Z.; Zhang, R.; … Zhao, Z.; Tang, B.Z.
    • Journal: ACS Nano
    • Year: 2023

 

  • Title: Multi-site isomerization of synergistically regulated stimuli-responsive AIE materials toward multi-level decryption
    • Authors: Zhong, W.; Zhang, J.; Lin, Y.; … Cai, X.-M.; Tang, B.Z.
    • Journal: Chemical Science
    • Year: 2024

 

  • Title: Chromene-based BioAIEgens: ‘in-water’ synthesis, regiostructure-dependent fluorescence and ER-specific imaging
    • Authors: Cai, X.-M.; Lin, Y.; Zhang, J.; … Zhao, Z.; Tang, B.Z.
    • Journal: National Science Review
    • Year: 2023

 

  • Title: Natural Acceptor of Coumarin-Isomerized Red-Emissive BioAIEgen for Monitoring Cu²⁺ Concentration in Live Cells via FLIM
    • Authors: Cai, X.-M.; Li, S.; Wang, W.-J.; … Zhao, Z.; Tang, B.Z.
    • Journal: Advanced Science
    • Year: 2024

 

  • Title: Room Temperature Phosphorescent Nanofiber Membranes by Bio-Fermentation
    • Authors: Nie, X.; Gong, J.; Ding, Z.; … Qiu, Z.; Tang, B.Z.
    • Journal: Advanced Science
    • Year: 2024

Prof. Hongsheng Liu | Pharmaco-Oncology | Best Researcher Award

Prof. Hongsheng Liu | Pharmaco-Oncology | Best Researcher Award

Liaoning University | China

Author Profile

Scopus

🌟 Professor Hongsheng Liu: A Pioneer in Microbiology and Bioinformatics

Professor, School of Pharmaceutical Sciences, Liaoning University, China

🔬 Academic and Professional Background

Professor Hongsheng Liu obtained a Master’s degree in Microbiology from China Agricultural University in 1991 and later pursued a Ph.D. in Microbiology and Bioinformatics at Gifu University School of Medicine, Japan, in 2004. Over the years, he has expanded his expertise by serving as a visiting scholar at prestigious institutions such as Wuhan University, the University of Hong Kong, Harvard Medical School, and Hebrew University of Jerusalem. His career reflects a deep commitment to advancing the fields of microbiology, bioinformatics, and pharmaceutical sciences.

💡 Research and Innovations

Professor Liu has completed an impressive 74 research projects and authored over 100 journal articles (SCI, Scopus, etc.), accumulating a citation index of 2721. His work spans diverse areas, including the discovery of the novel microorganism Paenibacillus liaoningensis sp. nov. and the investigation of influenza virus interactions. His contributions to computational biology include the development of several predictive algorithms and online platforms like CarcinoPred-EL and LiverToxPred-EL. Additionally, Professor Liu holds 37 patents, has published 4 books, and has led 7 industry consultancy projects.

📚 Published Works and Collaborations

Professor Liu’s collaborative research includes partnerships with renowned institutions such as the University of Toledo, Harvard Medical School, and Eberhard Karl University of Tübingen. He has also served as a guest editor for Frontiers in Microbiology (2017-2018). His dedication to both basic and applied research continues to push the boundaries of pharmaceutical sciences.

👥 Professional Memberships

He is an active member of the Chinese Society for Microbiology (CSM) and the Chinese Chemical Society (CCS).

🌍 Areas of Research

Professor Liu specializes in computer-aided drug design and the simulation of biomacromolecule interactions, with a focus on studying lncRNAs and disease relationships, and designing stable recombinant proteins using engineered bacteria.

🔔 Conclusion

Professor Hongsheng Liu stands as a distinguished leader in microbiology and bioinformatics, contributing significantly to drug design, biomolecular simulation, and microbial discovery. His broad academic collaborations, cutting-edge innovations, and vast research output underscore his influence in the scientific community. Through his extensive work on predictive algorithms, microbial databases, and recombinant protein design, he has made impactful advancements in pharmaceutical sciences. With over 100 journal publications, 37 patents, and numerous prestigious collaborations, Professor Liu’s dedication to advancing scientific knowledge and improving human health is truly commendable.

📊🔬NOTABLE PUBLICATION:

    • Article Title: Ensemble multiclassification model for aquatic toxicity of organic compounds
      Authors: Li, X., Liu, G., Wang, Z., Liu, H., Ai, H.
      Journal: Aquatic Toxicology
      Year: 2023

     

    • Article Title: Construction of an oxidative stress-related lncRNAs signature to predict prognosis and the immune response in gastric cancer
      Authors: Zhang, H., Feng, H., Yu, T., Ma, L., Liu, H.
      Journal: Scientific Reports
      Year: 2023

     

    • Article Title: CBIL-VHPLI: a model for predicting viral-host protein-lncRNA interactions based on machine learning and transfer learning
      Authors: Zhang, M., Zhang, L., Liu, T., Zhao, J., Liu, H.
      Journal: Scientific Reports
      Year: 2024

     

    • Article Title: Construction of highly active and stable recombinant nattokinase by engineered bacteria and computational design
      Authors: Wang, L., Meng, J., Yu, X., Zhang, L., Liu, H.
      Journal: Archives of Biochemistry and Biophysics
      Year: 2024

     

    • Article Title: Effects of dietary supplementation of gallic tannic acid on growth, intestinal digestive enzymes activity, innate immunity, morphology, and microbial composition of Cyprinus carpio
      Authors: Feng, H., Zhao, S., Ma, X., Liu, Z., Liu, H.
      Journal: Aquaculture International
      Year: 2024

Prof. IsabellaCavalcanti – Cancer Science – Best Researcher Award

Prof. IsabellaCavalcanti - Cancer Science - Best Researcher Award

Federal University of Pernambuco (UFPE) - Brazil

Author Profile

Google Scholar 

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Isabella Macário Ferro Cavalcanti began her academic journey by graduating in Biomedicine from the Federal University of Pernambuco (UFPE). Following this, she pursued a master's degree in Therapeutic Innovation at UFPE, delving into advanced studies in the field. She then proceeded to earn her doctorate in Biotechnology, further refining her expertise in biological sciences.

PROFESSIONAL ENDEAVORS

Dr. Cavalcanti's professional career has been marked by significant accomplishments. She specializes in Clinical Microbiology, obtaining further specialization at the University of Pernambuco (UPE). Currently, she serves as a professor at UFPE, where she contributes to the education and training of future professionals in the field. Her involvement extends to leadership roles within various post-graduate programs, emphasizing her dedication to academic advancement.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER SCIENCE

Dr. Cavalcanti's research endeavors are diverse and impactful. As the Head and Researcher of Clinical Microbiology at the Laboratory of Immunopathology Keizo Asami at UFPE (LIKA/UFPE), she spearheads investigations into drug delivery systems and their biological activities. Her research group, MicroNAT, focuses on innovative approaches to combat multi-drug-resistant bacteria and biofilm formation. Through her work, she seeks to advance pharmaceutical nanotechnology and fundamental microbiological understanding.

IMPACT AND INFLUENCE

Isabella Macário Ferro Cavalcanti's contributions have had a profound impact on the fields of pharmaceutical nanotechnology and microbiology. Her research findings contribute to the development of novel therapeutic strategies and the understanding of microbial resistance mechanisms. As a respected member of the Brazilian Society of Microbiology and various scientific committees, her expertise is recognized nationally and internationally.

ACADEMIC CITATIONS

Dr. Cavalcanti's work has garnered significant attention within the academic community, reflected in numerous citations of her research publications. Her contributions to scientific literature serve as a foundation for further exploration and innovation in the fields of biotechnology, microbiology, and drug delivery.

LEGACY AND FUTURE CONTRIBUTIONS

With a strong foundation in academia and research, Dr. Cavalcanti's legacy is marked by her dedication to advancing knowledge and addressing critical healthcare challenges. Her leadership in research groups and academic programs ensures the continued development of future scientists and the pursuit of innovative solutions to complex biomedical problems. As she continues her career, her contributions are poised to further shape the landscape of biomedicine and microbiology, leaving a lasting legacy of excellence and innovation.

NOTABLE PUBLICATIONS

Zein nanoparticles containing ceftazidime and tobramycin: antibacterial activity against Gram-negative bacteria. 2024

Proteomic characterization and biological activities of the mucus produced by the zoanthid Palythoa caribaeorum (Duchassaing & Michelotti, 1860) 2023

Efficacy and non-toxicity of ciclopirox olamine-loaded liposomes against Cryptococcus neoformans clinical isolates. 2023

Gram-negative bacilli carrying mcr gene in Brazil: a pathogen on the rise. 2023

Antibiotic resistance profiles on pathogenic bacteria in the Brazilian environments. 2023